Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Propoxyphene
Drug ID BADD_D01865
Description Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Indications and Usage For the relief of mild to moderate pain.
Marketing Status approved; illicit; investigational; withdrawn
ATC Code N02AC04
DrugBank ID DB00647
KEGG ID D00482; D07809
MeSH ID D011431
PubChem ID 10100
TTD Drug ID D0D4PB
NDC Product Code Not Available
UNII S2F83W92TK
Synonyms Dextropropoxyphene | Propoxyphene | D-Propoxyphene | D Propoxyphene | Propoxyphene Hydrochloride | Hydrochloride, Propoxyphene | Propoxyphene Hydrochloride, (R*,R*)-(+-)-Isomer | Propoxyphene Sulfate, (S-(R*,S*))-Isomer | Propoxyphene Hydrochloride, (R-(R*,S*))-Isomer | Propoxyphene Hydrochloride, (S-(R*,R*))-Isomer | Propoxyphene Maleate, (+)-Isomer | Propoxyphene Phosphate, (S-(R*,S*))-Isomer | Darvon | Propoxyphene Hydrochloride, (R-(R*,R*))-Isomer
Chemical Information
Molecular Formula C22H29NO2
CAS Registry Number 469-62-5
SMILES CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic steatosis14.08.04.005; 09.01.07.003--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hepatomegaly09.01.05.001--Not Available
Hip fracture15.08.03.001; 12.04.01.001--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.004--Not Available
Metabolic acidosis14.01.01.003--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Pancreatitis acute07.18.01.002--Not Available
Rash23.03.13.001--Not Available
Respiratory arrest22.02.01.009--Not Available
Respiratory depression17.02.05.047; 22.02.01.010--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Drug tolerance08.06.01.003--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages